Pharmaceuticals

An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS | April 14, 2017

April 14, 2017 — The Heart Rhythm Society (HRS) has announced its late-breaking clinical trials at its annual...

EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017

April 3, 2017 — There is no evidence that adding a new...

Ablation procedure, EP lab, Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation
Feature | Atrial Fibrillation | March 29, 2017

March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K,...

synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals | March 29, 2017

March 29, 2017 — Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good...

PCI, drugs, medication, fully blocked arteries, chronic total occlusion, ACC.17, clinical study
News | Chronic Total Occlusion (CTO) | March 29, 2017 | Dave Fornell

March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal...

heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals | March 28, 2017

March 28, 2017 — When used as a preventive measure during heart surgery, the heart failure...

ECRI Institute, top 10 patient safety concerns, 2017 report, information technology, healthcare
News | Information Technology | March 24, 2017

March 24, 2017 — Safe implementation of...

bleeding complications, rivaroxaban, antiplatelet therapy, post-ACS, acute coronary syndrome, ACC.17 study
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — Bleeding complications did not increase for patients with acute coronary syndrome treated with...

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low...

PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals | March 22, 2017

March 22, 2017 — In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when...

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals | March 20, 2017

March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology...

warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017

March 14, 2017 — More than 80 percent of stroke patients with a history of...

CeloNova Cobra Pzf stent
Technology | Stents | March 02, 2017

March 2, 2017 — The U.S. Food and Drug Administration (FDA) cleared CeloNova BioSciences Inc. first-in-class Cobra...

Overlay Init